The acquisition has been done in order to support Roche’s plan to develop full line of coagulation analyzer in US and Canada and introduce them in 2014.

As per the agreement, Roche will pay Verum’s shareholders a total cash consideration of 11m euros and upon reaching certain performance-related milestones it will also pay 2m euros.

Roche Professional Diagnostics head Colin Brown said with this acquisition they gain a platelet function testing solution which has the potential to set new standards of patient care in this area and complements their new coagulation portfolio.